Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Patricia A. Walicke"'
Autor:
Patricia A. Walicke, Franz Hefti, Roxanne Bales, Shiao-Ping Lu, Jon L. Ruckle, Mark T. Brown, Christine R. West, David L. Shelton
Publikováno v:
PAIN Reports, Vol 3, Iss 3, p e653 (2018)
Abstract. Introduction:. The neurotrophin nerve growth factor has a demonstrated role in pain transduction and pathophysiology. Objectives:. Two randomized, double-blind, placebo-controlled, phase 1 studies were conducted to evaluate safety, tolerabi
Externí odkaz:
https://doaj.org/article/a23e1a0f593f4e798fc68720c1f36903
Autor:
David L. Shelton, Shiao-Ping Lu, Roxanne Bales, Mark T. Brown, Patricia Ann Walicke, Jon L Ruckle, Franz F. Hefti, Christine R. West
Publikováno v:
PAIN Reports, Vol 3, Iss 3, p e653 (2018)
Introduction:. The neurotrophin nerve growth factor has a demonstrated role in pain transduction and pathophysiology. Objectives:. Two randomized, double-blind, placebo-controlled, phase 1 studies were conducted to evaluate safety, tolerability, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4704e39a798c8c715d52aeaa0dc85dfe
https://doi.org/10.1097/pr9.0000000000000653
https://doi.org/10.1097/pr9.0000000000000653
Autor:
Alan Menter, Patricia A. Walicke, Ivor Caro, Scott Fretzin, Kenneth B. Gordon, Steven Kempers, Bernard S. Goffe, Reni Bressinck, Kim A. Papp, Xiaolin Wang
Publikováno v:
International Journal of Dermatology. 45:605-614
Background To provide safety data for efalizumab, a recombinant humanized monoclonal IgG1 antibody, in adults with chronic plaque psoriasis. Methods A 12-week, Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled trial. At 58 stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5951030e41d97cafc819342ad8fd9582
https://doi.org/10.1111/j.1365-4632.2006.02777.x
https://doi.org/10.1111/j.1365-4632.2006.02777.x
Autor:
Peter Compton, Mark Lebwohl, David M. Pariser, Kenneth B. Gordon, Amy Chen Rundle, Patricia A. Walicke, Kim A. Papp, Paul Kwon, Craig L. Leonardi
Publikováno v:
Journal of Cutaneous Medicine and Surgery. 9:303-312
Background: Effective psoriasis therapies are needed for long-term symptom control. ObjectiveAssess efalizumab (Raptiva®) efficacy in a large cohort of psoriasis patients. Methods: Data from three Phase III, randomized, double-blind, parallel-group,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::148b8191c3f1a3a6b46cdca30a5e5d58
https://doi.org/10.1007/s10227-005-0116-1
https://doi.org/10.1007/s10227-005-0116-1
Autor:
Kim A. Papp, Charles Camisa, Alice B. Gottlieb, Xiaolin Wang, Stephen P. Stone, Ivor Caro, Patricia A. Walicke, Peter Compton
Publikováno v:
Journal of Cutaneous Medicine and Surgery. 9:313-323
Background: The efficacy and safety of efalizumab have been evaluated in multiple clinical trials. ObjectiveThe purpose of this review is to provide an overview of the safety profile of efalizumab during the clinical trials. Methods: Twelve-week data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a53615eba9abf3b734433c408286585
https://doi.org/10.1177/120347540500900607
https://doi.org/10.1177/120347540500900607
Autor:
Peter Compton, Ivor Caro, Steven R. Feldman, Kim A. Papp, Alice B. Gottlieb, Alan Menter, Patricia A. Walicke, Craig L. Leonardi, Kenneth B. Gordon
Publikováno v:
Journal of the American Academy of Dermatology. 52:425-433
Efalizumab inhibits multiple T-cell-mediated processes.To evaluate 12- and 24-week efalizumab therapy for psoriasis.In this phase III, randomized, double-blind trial, 498 patients received subcutaneous 1 or 2 mg/kg/wk efalizumab or placebo for 12 wee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec316db0c6cd2409bb3b1c0c4243d937
https://doi.org/10.1016/j.jaad.2004.09.029
https://doi.org/10.1016/j.jaad.2004.09.029
Autor:
Alice B. Gottlieb, Patricia A. Walicke, Nicholas J. Lowe, Ross Bright, Robert J. Bauer, Charles Hudson, Toivo Rist, Anna Magee, Wolfgang Dummer, Mark White, William Shapiro, Bruce E. Miller, Marvin Garovoy, Calvin O. McCall, Mark Ling
Publikováno v:
Journal of Cutaneous Medicine and Surgery. 7:198-207
Background: Phase I and Phase II studies in patients with moderate to severe plaque psoriasis demonstrated that intravenous (TV) efalizumab improved clinical signs and symptoms and was well tolerated. Objective: To determine if subcutaneous (SC) deli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::417528a57cb8459bc2eed0368d2e75b9
https://doi.org/10.1177/120347540300700303
https://doi.org/10.1177/120347540300700303
Publikováno v:
Transplant Immunology. 9:181-186
The acquired immune response that leads to graft rejection depends on regulated adhesive interactions between T lymphocytes, endothelial cells, dendritic cells, graft tissue and the extracellular matrix to coordinate cellular trafficking and activati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24611ef0454302137b35e5c69f26cecc
https://doi.org/10.1016/s0966-3274(02)00029-1
https://doi.org/10.1016/s0966-3274(02)00029-1
Autor:
Harvey Lui, Russell L. Dedrick, Neil H. Shear, Mark White, Kim A. Papp, Charles Lynde, Wayne Gulliver, Wayne Carey, Robert Bissonnette, Robert J. Bauer, David Gratton, Marvin Garovoy, Sun Sook Kim, James G. Krueger, Susan M. Kramer, Jerry Shapiro, Daniel Minier, Piyush M. Patel, Patricia A. Walicke, Jean P. Ouellet, Anna Magee
Publikováno v:
Journal of the American Academy of Dermatology. 45:665-674
Anti-CD11a (hu1124) is a humanized monoclonal antibody directed against the CD11a subunit of LFA-1. This study investigated whether treatment with anti-CD11a antibody provides clinical benefit to patients with moderate to severe plaque psoriasis.This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3fad6974cbdcd25da2af1a5539b4b53
https://doi.org/10.1067/mjd.2001.117850
https://doi.org/10.1067/mjd.2001.117850
Autor:
Franz Hefti, Patricia Ann Walicke, Jasna Jerecic, Grant A. Krafft, Kent S. Iverson, William F. Goure
Publikováno v:
Alzheimer's & Dementia. 9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d73e4757b8503b99734da3cac7021cbe
https://doi.org/10.1016/j.jalz.2013.04.166
https://doi.org/10.1016/j.jalz.2013.04.166